Menopausal hormone therapy: a better and safer future

@article{Davey2018MenopausalHT,
  title={Menopausal hormone therapy: a better and safer future},
  author={D A Davey},
  journal={Climacteric},
  year={2018},
  volume={21},
  pages={454 - 461}
}
  • D. Davey
  • Published 11 March 2018
  • Medicine
  • Climacteric
Abstract Major advances in menopause hormone therapy (MHT) hold promise in the future of better and safer care for women at and after the menopause. The principal advances are: (1) the critical window or ‘window of opportunity’ in the 10 years or so after the menopause, during which the benefits of MHT in healthy women exceed any risks; (2) use of transdermal instead of oral administration of estrogen to reduce the risk of venous thromboembolism; (c) investigation of the use of oral micronized… 

Menopausal osteoporosis: screening, prevention and treatment.

Treatment should be considered in women with previous fragility fractures, DEXA-diagnosed osteoporosis and high risk of fracture, and women should ensure adequate calcium intake and vitamin D.

Effects of estradiol supplementation on the brain transcriptome of old rhesus macaques maintained on an obesogenic diet

The results suggest that a chronic obesogenic diet may induce a wide range of alterations in multiple signaling pathways that are linked to age-associated brain pathology and dementia in postmenopausal women, and HT seems to have a protective effect against neuroinflammation, amyloid beta depositions, and tau tangle formation.

Relação entre terapia de reposição hormonal no climatério e o desenvolvimento de neoplasias.

The use of progestogens has been shown to be of greater benefit in women with a history of endometriosis or endometrial CA, and the HRT decision must respect the physiological and family history of each woman.

Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study

The findings support a protective effect of estrogen on CO VID-19, based on positive association between predicted COVID-19 and menopausal status, and a negative association with COCP use.

Interactions between estradiol, diabetes, and brain aging and the risk for cognitive impairment

This review summarizes existing literature from randomized trials, observational studies, and preclinical studies to provide a fundamental understanding of the effects of the interaction between T2DM and HT on cognitive and metabolic health changes in brain aging.

The Impact of Estrogen and Estrogen-Like Molecules in Neurogenesis and Neurodegeneration: Beneficial or Harmful?

A comprehensive literature review on the current knowledge of estrogen and estrogen-like molecules and their impact on cell survival and neurodegeneration, as well as their role in NSPCs proliferation/differentiation balance and neurogenesis is provided.

References

SHOWING 1-10 OF 63 REFERENCES

Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?

It is suggested that, for some EP-MHT, the timing of treatment initiation transiently modulates the risk of breast cancer and that, when initiated close to menopause, even short durations of use are associated with an increased breast cancer risk.

Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.

Oral estradiol therapy was associated with less progression of subclinical atherosclerosis (measured as CIMT) than was placebo when therapy was initiated within 6 years after menopause but not when it was initiated 10 or more years afterMenopause.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial

Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.

Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition.

The finding of a strong increased risk of endometrial cancer with estrogen-only HT and a weaker association with combined HT supports the hypothesis that progestins have an attenuating effect on endometricrial cancer risk.

The impact of micronized progesterone on the endometrium: a systematic review

Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection, according to an international expert panel’s recommendations on MHT containing micronized progesterone.

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

Oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit.

Progesterone – promoter or inhibitor of breast cancer

  • H. KuhlH. Schneider
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2013
Similar to other progestogens, hormone replacement therapy with progesterone seems to promote the development of breast cancer, provided that the progester one serum levels have reached the threshold for endometrial protection.

Hormone therapy for preventing cardiovascular disease in post-menopausal women.

High quality evidence is found that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality, cardiovascular death, non-fatal myocardial infarction, angina, or revascularisation; the findings are dominated by the three largest trials.

Postmenopausal hormone therapy: new questions and the case for new clinical trials

There is now a critical mass of data to support the hypothesis that age or time since menopause may importantly influence the benefit-risk ratio associated with HT, especially with respect to cardiovascular outcomes, and that the method of administration, dose, and formulation of exogenous hormones may also be relevant.
...